Navigation Links
Agendia Appoints VP of Business Development
Date:2/11/2009

HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, February 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Alan B. Carter as the company's new Vice President of Global Business Development.

"As we continue to grow as a global company, Alan's appointment furthers one of our primary aims," commented Dr. Bernhard Sixt, Ph.D., President and Chief Executive Officer. "His extensive business development expertise will strengthen our ongoing programs and pipeline projects and also allows us to capitalize on our genomics platform in close collaboration with biotechnology and pharmaceutical partners. With Alan's involvement, Agendia will continue to play a central role in making targeted therapies one of the cornerstones of personalized medicine."

Mr. Carter brings 25 years of business development, sales and marketing experience from a number of top tier life sciences companies such as BioTrove, Celera, Applied Biosystems and Perkin Elmer. At Agendia, Mr. Carter will assume responsibility for strategic business opportunities to build on the current success of Agendia's molecular diagnostics portfolio. This products suite includes MammaPrint(R), the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role in forging Agendia's strategic alliances with pharmaceutical and biotech companies to accelerate the use of molecular diagnostics in drug development, companion diagnostics and safety testing programs.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... ... leading Chinese bio security firm, to bring its proprietary CANARY pathogen detection technology ... the relationship, the Chinese firm has purchased an undisclosed number of PathSensors’ Zephyr ...
(Date:8/18/2017)... ... 18, 2017 , ... OAI, a leading Silicon Valley, CA-based ... announces the new Model 800E front and backside, semi-automatic mask aligner system. This ... OAI has already received and installed several orders for the Model ...
(Date:8/16/2017)... Yorba Linda, Ca (PRWEB) , ... August 16, ... ... resist treatment by changing into a different cell type. Many treatments for specific ... tissue. A prominent example of targeted treatment is androgen deprivation therapy for advanced ...
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
Breaking Biology Technology:
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):